share_log

Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $23 Price Target

Benzinga ·  Jul 16 10:46

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment